Clinical safety and efficacy of a novel thermoreversible polyhexanide-preserved wound covering gel

European Surgical Research

Volumn 44, Issue 2, 2010, Pages 96-101

  Goertz, O ^a   Abels, C ^b   Knie, U ^b   May, T ^c   Hirsch, T ^a   Daigeler, A ^a   Steinau, H U ^a   Langer, S ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Dr August Wolff GmbH and Co KG Arzneimittel   (Germany)

^c Institute for Biometry and Psychometry (GBP)   (Germany)

Author keywords

Flammazine; Wound gel, clinical safety, efficacy; Wound therapy

Indexed keywords

ANTIINFECTIVE AGENT; POLYHEXANIDE; POLYMER; POVIDONE IODINE; SULFADIAZINE SILVER; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GEL; HUMAN; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WOUND CARE; WOUND DRESSING;

ADULT; AGED; ANTI-INFECTIVE AGENTS, LOCAL; BANDAGES; BIGUANIDES; FEMALE; GELS; HUMANS; INFORMED CONSENT; MALE; MIDDLE AGED; OINTMENTS; PATIENT SELECTION; SAFETY; SILVER SULFADIAZINE; SKIN TRANSPLANTATION; VISCOSITY; WOUNDS AND INJURIES;

EID: 74249091157     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276303     Document Type: Article

References (22)

1. Suh DY, Hunt TK: Time line of wound healing. Clin Podiatr Med Surg 1998; 15: 1-9.
2. Muller G, Kramer A: Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother 2008; 61: 1281-1287.
3. Dumortier G, et al: A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23: 2709-2728.
4. Kramer A, et al: Influence of the antiseptic agents polyhexanide and octenidine on FL cells and on healing of experimental superficial aseptic wounds in piglets: a doubleblind, randomised, stratified, controlled, parallel-group study. Skin Pharmacol Physiol 2004; 17: 141-146.
5. Hermans MH: Results of an internet survey on the treatment of partial thickness burns, full thickness burns, and donor sites. J Burn Care Res 2007; 28: 835-847.
6. Daeschlein G, et al: Feasibility and clinical applicability of polyhexanide for treatment of second-degree burn wounds. Skin Pharmacol Physiol 2007; 20: 292-296.
7. Goertz O, et al: Evaluation of a novel polyhexanide- preserved wound covering gel on dermal wound healing. Eur Surg Res 2010; 44: 23-29.
8. Langer S, et al: The impact of topical antiseptics on skin microcirculation. Eur J Med Res 2004; 9: 449-454.
9. Kalteis T, et al: Tissue toxicity of antiseptics. Z Orthop Ihre Grenzgeb 2003; 141: 233-238.
10. Hirsch T, et al: A comparative in vitro study of cell toxicity of clinically used antiseptics. Hautarzt 2009;60:984-991.
11. Muller G, Kramer A: Effect of selected wound antiseptics on adult articular cartilage (bovine sesamoid bone) in the presence of Escherichia coli and Staphylococcus aureus . J Orthop Res 2005; 23: 127-133.
12. Mintz EM, George DE, Hsu S: Silver sulfadiazine therapy in widespread bullous disorders: potential for toxicity. Dermatol Online J 2008; 14: 19.
13. Rietkotter J, et al: Eradication of methicillinresistant Staphylococcus aureus in a chronic wound by a new polyhexanide hydrogel. J Eur Acad Dermatol Venereol 2007; 21: 1416-1417.
14. Ansorg R, Rath PM, Fabry W: Inhibition of the anti-staphylococcal activity of the antiseptic polihexanide by mucin. Arzneimittelforschung 2003; 53: 368-371.
15. Stratton LP, et al: Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. J Pharm Sci 1997; 86: 1006-1010.
16. Collaud S, et al: Thermosetting gel for the delivery of 5-aminolevulinic acid esters to the cervix. J Pharm Sci 2008; 97: 2680-2690.
17. Ricci EJ, et al: Sustained release of lidocaine from poloxamer 407 gels. Int J Pharm 2005; 288: 235-244.
18. Wout ZG, et al: Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 1992; 46: 192-200.
19. Hemstreet BA, Page RL 2nd: Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy 2006; 26: 551-557.
20. Aoyagi H, Iwasaki SI: Long-term effect of silver powder in vivo. Dent Mater J 2008; 27: 612-625.
21. Trop M, et al: Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 2006; 60: 648-652.
22. Tomljanovic-Veselski M, Lipozencic J, Lugovic L: Contact allergy to special and standard allergens in patients with venous ulcers. Coll Antropol 2007; 31: 751-756.